IL6 and neoplasm: This dual modulation of inflammatory mediators—suppressing chronic inflammation (IL-1β, IFN-γ) while inducing acute immune activation (IL-6, TNF-α)—may reprogram the tumor microenvironment toward an immune-permissive state.